Stockscreener 앱 받기
3.065
10.65%
0.295
시간 외 거래:
3.06
-0.005
-0.16%
전일 마감가:
$2.77
열려 있는:
$2.81
하루 거래량:
5.67M
Relative Volume:
1.28
시가총액:
$270.42M
수익:
-
순이익/손실:
$-258.08M
주가수익비율:
-1.1145
EPS:
-2.75
순현금흐름:
$-202.32M
1주 성능:
+22.11%
1개월 성능:
-51.43%
6개월 성능:
-77.93%
1년 성능:
-86.67%
1일 변동 폭
$2.81
$3.185
1주일 범위
$2.4699
$3.185
52주 변동 폭
$2.19
$26.98
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
명칭
Rocket Pharmaceuticals Inc
전화
646-440-9100
주소
350 FIFTH AVENUE, NEW YORK, NY
RCKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.065 | 270.42M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-30 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-05-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-28 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-28 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | 다운그레이드 | Needham | Buy → Hold |
| 2025-05-27 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-30 | 개시 | Wedbush | Outperform |
| 2024-12-18 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 개시 | Morgan Stanley | Overweight |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2022-11-01 | 개시 | BTIG Research | Buy |
| 2022-07-08 | 개시 | Raymond James | Outperform |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 개시 | JP Morgan | Overweight |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2019-11-06 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-26 | 개시 | Piper Jaffray | Overweight |
| 2019-04-23 | 개시 | Robert W. Baird | Outperform |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-02-05 | 개시 | Oppenheimer | Outperform |
| 2018-09-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-10 | 개시 | William Blair | Outperform |
모두보기
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Did You Suffer Losses in Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.
Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) Over Possible Securities Fraud - ACCESS Newswire
Levi & Korsinsky Launches Fraud Investigation on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders - ACCESS Newswire
(RCKT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $11.00 by Analysts at Canaccord Genuity Group - Defense World
RCKT ALERT: Ongoing Investigation Into Rocket Pharmaceuticals, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Rocket Pharmaceuticals (RCKT) Target Price Lowered by Canaccord Genuity | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Reduced Price Target Amid Cl - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Reduced Price Target Amid Clinical Hold Challenges | RCKT Stock News - GuruFocus
Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) Stock, Slashes PT - MSN
FY2025 Earnings Estimate for RCKT Issued By Chardan Capital - Defense World
Ongoing Investigation: Rocket Pharmaceuticals, Inc. (RCKT) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - WV News
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Bank of America Corp DE - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Lowered to In-Line Rating by Evercore ISI - Defense World
Wedbush Brokers Increase Earnings Estimates for RCKT - Defense World
Leerink Partnrs Issues Optimistic Forecast for RCKT Earnings - Defense World
Securities Investigation: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) on Behalf of Investors - ACCESS Newswire
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Rocket Pharmaceuticals (RCKT) Faces Downgrade with New Price Tar - GuruFocus
RCKT ACTIVE INVESTIGATION: Lost Money on Rocket Pharmaceuticals, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setba - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setback | RCKT Stock News - GuruFocus
Evercore ISI Downgrades Rocket Pharmaceuticals to In Line From Outperform, $5 Price Target - marketscreener.com
Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) to In Line, 'removing from the SMID Core List' - StreetInsider
Jane Street Group LLC Has $508,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Millennium Management LLC Sells 865,586 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to “Hold” at Leerink Partnrs - Defense World
Equities Analysts Issue Forecasts for RCKT Q2 Earnings - Defense World
Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Rocket Pharmaceuticals (NASDAQ:RCKT) Given Hold Rating at Jefferies Financial Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Downgraded to “Sell” Rating by The Goldman Sachs Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to Sell at The Goldman Sachs Group - Defense World
RCKT ALERT: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies - MSN
Rocket Pharmaceuticals’ (RCKT) “Hold” Rating Reaffirmed at Jefferies Financial Group - Defense World
Rocket Pharmaceuticals’ (RCKT) “Market Perform” Rating Reaffirmed at Leerink Partners - Defense World
William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback - MSN
JPMorgan Downgrades Rocket Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $7 From $44 - marketscreener.com
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move. - AOL.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Given New $19.00 Price Target at Scotiabank - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $9.00 at Bank of America - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives “Hold” Rating from Jefferies Financial Group - Defense World
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow - Insider Monkey
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty - Benzinga
Rocket Pharmaceuticals (RCKT) Faces Downgrade After Clinical Hol - GuruFocus
Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact - Seeking Alpha
Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death - MSN
Rocket Pharmaceuticals (RCKT) Analyst Rating Update: May 2025 | - GuruFocus
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Scotiabank - GuruFocus
Rocket Pharmaceuticals Inc (RCKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.51%
자본화:
|
볼륨(24시간):